Coverage
-
April 19, 2018
A Virginia federal judge signed off Wednesday on Pfizer's $94 million settlement, including nearly $31 million in legal fees, with drug buyers who said the pharmaceutical giant extended its monopoly over the anti-inflammatory Celebrex by illegally blocking generic competition.
5 other articles on this case.
View all »